Prelude Therapeutics Incorporated Q4 FY2025 earnings call

Discussed aspects such as the clinical development plan for molecule 396 including a parallel design in myelofibrosis and polycythemia vera with input from key opinion leaders, the rationale behind choosing a degrader approach for CAT6 including selectivity and efficacy advantages, and work on the mutant Cal-R degrader with differentiation points like potency and potential for subcutaneous administration.

Not explicitly mentioned in detail

Cash position was $106 million in cash, which takes the company into the second quarter of 2027, and this does not account for the potential $100 million option payment from Insight.

Not discussed in detail

Q: Can you differentiate your molecule from other competitors and why Insight would partner with you?

A: Discussed selectivity profile, learnings from clinic/preclinical stages, and parallel clinical development plan.

Q: Talk about the clinical development plan for molecule 396?

A: Parallel design in myelofibrosis and polycythemia vera, enrolling the right patients and getting FDA approval for the parallel approach.

Q: Talk about the CAT6 degrader?

A: Differentiated by degrader approach for better selectivity and efficacy, plan to file IND by mid - year.

Q: What is the cash position?

A: $106 million in cash, lasting into the second quarter of 2027